Lower prescription drug costs.

Marilyn is dedicated to lowering the cost of prescription drugs and is a cosponsor of legislation allowing Medicare to negotiate drug prices, resulting in lower drug prices for those on private insurance as well as Medicare.

Commitment to reduce drug prices by allowing Medicare to negotiate prices.

Universal Health Care - Marilyn Strickland For Congress
campaign · campaign_site · model gpt-5.4-mini

In Congress, Marilyn will fight to give Medicare the power to negotiate drug prices, forcing pharmaceutical companies to lower prices across the board.

Commits to empowering Medicare to negotiate drug prices to reduce prescription costs.

Strickland-Healthcare-Plan.pdf
campaign · other · model gpt-5.4-mini

CMS posted a May 26, 2026 Selected Drug List and Negotiated Prices file containing negotiated maximum fair prices, and says 2028 negotiations are underway with participating manufacturers.

Recent official implementation record shows Medicare drug price negotiation is active, with negotiated prices published for selected drugs and later negotiation cycles continuing.

partial later_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.5 · confidence 93%

The Supreme Court order list placed AstraZeneca, Janssen, Bristol Myers Squibb, Novo Nordisk, and Boehringer Ingelheim Medicare negotiation cases under CERTIORARI DENIED.

Within the lookback window, the Supreme Court declined review of major drugmaker challenges, leaving the Medicare negotiation program in place rather than blocked by those appeals.

partial later_term

051826zor_h315.pdf
secondary · model gpt-5.5 · confidence 92%

CMS announced eligible Medicare Part D beneficiaries will be able to access certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027.

Recent agency action provides a concrete upcoming reduction in out-of-pocket costs for a costly drug class for eligible Medicare beneficiaries, though it is limited and time-limited.

partial later_term

CMS: Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
secondary · model gpt-5.5 · confidence 87%

CMS says all Medicare prescription drug plans must offer Part D enrollees the option to pay out-of-pocket prescription drug costs through capped monthly payments.

The IRA-created payment smoothing program is in effect for Medicare Part D enrollees, reducing large upfront pharmacy bills, though it does not reduce total annual drug prices by itself.

partial later_term

CMS: Medicare Prescription Payment Plan
secondary · model gpt-5.5 · confidence 90%

CMS says it assessed inflation rebates to manufacturers that raised certain Medicare Part B and Part D drug prices faster than inflation, and Part B coinsurance can be lower for rebatable drugs.

Official implementation of IRA inflation rebates shows another operational mechanism lowering some beneficiary coinsurance and penalizing faster-than-inflation price increases.

partial later_term

CMS: Medicare Inflation Rebate Program
secondary · model gpt-5.5 · confidence 91%

On August 12, 2022, H.R. 5376 passed the House 220-207; the Clerk records Rep. Strickland, Democrat of Washington, voting Yea.

Strickland took a concrete same-term vote for the Inflation Reduction Act, the enacted vehicle for Medicare negotiation, insulin caps, inflation rebates, and Part D out-of-pocket protections.

partial same_term A for effort

Office of the Clerk: Roll Call 420, H.R. 5376
secondary · model gpt-5.5 · confidence 96%

Congress.gov summarizes P.L. 117-169 as eliminating Medicare Part D adult vaccine cost-sharing, expanding low-income subsidies, capping Medicare insulin cost-sharing, and implementing drug pricing reforms.

The bill Strickland supported became law and contains multiple prescription-drug affordability provisions, establishing partial fulfillment of the broad lower-drug-costs commitment.

partial same_term

Congress.gov: H.R.5376, Inflation Reduction Act of 2022, All Information
secondary · model gpt-5.5 · confidence 94%

Congress.gov says Sec. 71203 modifies the Medicare Drug Price Negotiation Program to exclude additional orphan drugs from negotiation beginning in 2028.

Later legislation narrowed part of the negotiation program, showing the drug-cost promise remains only partially delivered and subject to rollback rather than fully resolved.

partial later_term

Congress.gov: H.R.1, Public Law 119-21, Summary
primary · model gpt-5.5 · confidence 88%